Recombinant Anti-HER2 x Anti-HER3 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-HER2 and anti-HER3 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Breast cancer; Gastric cancer; Prostate cacncer; Ovarian cancer; Solid tumors therapy.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY